Comparing the Efficacy of Desidustat Versus Erythropoietin in the Management of Anemia in Patients With Dialysis-Naïve Chronic Kidney Disease: A Randomized Open-Label Trial
Desidustat was non-inferior to erythropoietin in treating anemia of dialysis-naïve CKD patients. Desidustat offers a safe and effective alternative to ESAs with better compliance.
Authors
- Waseem Rizvi (ORCID: https://orcid.org/0000-0003-0850-090X)
- Saif Quaiser (ORCID: https://orcid.org/0000-0003-3700-6089)
- Hiramani rabha (ORCID: https://orcid.org/0000-0002-4329-6652)
- Syed Shariq Naeem
Institutions
- Jawaharlal Nehru Medical College Hospital (IN)
Publication Details
- Journal
- Cureus
- Published
- 2026-02-15
- DOI
- https://doi.org/10.7759/cureus.103690
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline
- Aligarh Muslim University